JSR Life Sciences reposted this
KRASG12C inhibitors have transformed cancer treatment by effectively targeting the KRASG12C mutation. By locking KRASG12C in an inactive state, these therapies inhibit tumor growth. However, acquired resistance poses a significant challenge, limiting their long-term effectiveness. To overcome this hurdle, we’ve developed multiple KRASG12C inhibitor-resistant tumor models: ➡️Pretreated PDX Models: Derived from patient tumors already resistant to KRASG12C inhibitors. ➡️Drug-Induced Resistant PDX Models: Developed in vivo to simulate resistance evolution. ➡️Gene-Engineered Resistant CDX Models: Created from gene-modified cell lines to replicate resistance mechanisms. Discover how these advanced models can enhance and expedite your drug development pipeline. ➡️ https://hubs.la/Q02_V7Sp0
